Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DTILNASDAQ:HOWLNASDAQ:IFRXNASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$4.53-5.4%$5.07$3.61▼$11.09$53.11M1.48187,596 shs73,209 shsHOWLWerewolf Therapeutics$1.25+5.0%$1.08$0.60▼$4.18$53.40M0.65442,846 shs380,193 shsIFRXInflaRx$0.79-0.3%$1.26$0.71▼$2.82$53.38M1.29287,597 shs232,029 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.42 million shs29.28 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences-5.43%-12.72%-1.09%-11.00%-51.81%HOWLWerewolf Therapeutics+5.04%-3.85%+8.70%+15.74%-56.60%IFRXInflaRx-0.28%+1.67%-57.14%-40.38%-48.51%ME23andMe0.00%0.00%0.00%-23.38%-94.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDTILPrecision BioSciences4.1625 of 5 stars3.53.00.04.60.61.71.3HOWLWerewolf Therapeutics3.0868 of 5 stars3.53.00.00.00.65.00.6IFRXInflaRx2.7415 of 5 stars3.53.00.00.02.61.70.6ME23andMeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDTILPrecision BioSciences 3.00Buy$47.00937.53% UpsideHOWLWerewolf Therapeutics 3.00Buy$8.33566.67% UpsideIFRXInflaRx 3.00Buy$6.60732.28% UpsideME23andMe 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ME, HOWL, IFRX, and DTIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025IFRXInflaRxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$2.005/29/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $3.005/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.005/8/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.004/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.003/28/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/26/2025IFRXInflaRxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDTILPrecision BioSciences$68.70M0.73N/AN/A$6.87 per share0.66HOWLWerewolf Therapeutics$1.88M29.83N/AN/A$1.65 per share0.76IFRXInflaRx$180K295.74N/AN/A$1.13 per share0.70ME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)HOWLWerewolf Therapeutics-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)IFRXInflaRx-$49.85M-$0.82N/AN/AN/A-33,362.70%-64.17%-53.39%8/6/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest ME, HOWL, IFRX, and DTIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 million3/26/2025Q4 2024DTILPrecision BioSciences-$2.09-$3.20-$1.11-$2.22$4.28 million$3.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDTILPrecision BioSciencesN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDTILPrecision BioSciences0.456.626.62HOWLWerewolf Therapeutics0.468.098.09IFRXInflaRxN/A5.284.86ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDTILPrecision BioSciences37.99%HOWLWerewolf Therapeutics64.84%IFRXInflaRx42.39%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipDTILPrecision BioSciences4.00%HOWLWerewolf Therapeutics23.60%IFRXInflaRx16.30%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDTILPrecision BioSciences20011.09 million10.64 millionNo DataHOWLWerewolf Therapeutics4044.87 million34.28 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionableME23andMe77026.83 million19.77 millionNot OptionableME, HOWL, IFRX, and DTIL HeadlinesRecent News About These CompaniesVenture Firm Plans $10 Million Bid for 23andMe Health-Care UnitJune 24 at 1:28 AM | news.bloomberglaw.comBidder emerges for 23andMe's Lemonaid Health unitJune 24 at 1:28 AM | bizjournals.comCan 23andMe sell customers' DNA data? Bankruptcy hearing continued FridayJune 20, 2025 | stltoday.com23andMe Bankruptcy Judge to Rule Soon on Genetic Data Asset SaleJune 20, 2025 | news.bloomberglaw.comThe Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the WeekJune 20, 2025 | wsj.com23andMe’s ex-CEO is trying to buy the company. A St. Louis judge could decide Friday.June 20, 2025 | stltoday.comICO Imposes 2.31 Million Pound Fine on 23andMeJune 19, 2025 | govinfosecurity.com23andMe Could Owe You Up to $10,000 After Its Data Breach SettlementJune 19, 2025 | cnet.com23andMe Bankruptcy Judge Rejects Texas Effort to Halt Data SaleJune 18, 2025 | news.bloomberglaw.comBattle for 23andMe (and its data) growsJune 18, 2025 | finance.yahoo.comGene data: British data protection fine for 23andmeJune 18, 2025 | heise.deOklahoma files federal lawsuit against 23andMeJune 17, 2025 | kgou.org23andMe fined millions by watchdog after ‘profoundly damaging’ cyber attack exposing genetic dataJune 17, 2025 | lbc.co.ukUK Watchdogs Fine 23andMe $3.1M for Data Security ViolationsJune 17, 2025 | msn.comAnne Wojcicki on genetic privacy, data security and the money behind her bid for 23andMeJune 17, 2025 | bizjournals.com23andMe co-founder wins bid to take back control of companyJune 17, 2025 | massdevice.comICO fines bankrupt 23andMe £2.3m for massive privacy breachJune 17, 2025 | sharecast.comAnne Wojcicki wins bid to buy back 23andMe for $305MJune 17, 2025 | medtechdive.comUK regulator fines 23andMe over massive genetic data breachJune 17, 2025 | biometricupdate.com23andMe co-founder Anne Wojcicki regains control of bankrupt genetic testing companyJune 17, 2025 | msn.comOne Tech Tip: How to protect your 23andMe genetic dataJune 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyME, HOWL, IFRX, and DTIL Company DescriptionsPrecision BioSciences NASDAQ:DTIL$4.53 -0.26 (-5.43%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$4.68 +0.15 (+3.20%) As of 06/23/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Werewolf Therapeutics NASDAQ:HOWL$1.25 +0.06 (+5.04%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.23 -0.02 (-2.00%) As of 06/23/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.InflaRx NASDAQ:IFRX$0.79 0.00 (-0.28%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$0.80 +0.01 (+0.88%) As of 06/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
